ReviewIMA fungus2025
Review in IMA fungus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Isolation, Identification, and Antimicrobial Activity of Secondary Metabolites fromJournal of fungi (Basel, Switzerland) · 2026Article
- Comprehensive morphological and phylogenetic analyses ofPersoonia · 2026Article
- In Vitro Modeling of Mycelium Biomass Growth Kinetics of the Novel Fungicolous SpeciesJournal of fungi (Basel, Switzerland) · 2026Article
- Study of the Cytotoxic and Wound Healing Activity of Polysaccharides fromMolecules (Basel, Switzerland) · 2026Article
- Polydosetins & pullularins-bioactive tetramic acids & cyclodepsipeptides from the endophytic and nematophagous fungus Polydomus karssenii.Natural products and bioprospecting · 2026Article
- Targeting Staphylococcus aureus Biofilms Through Aurisin Derivatives From Neonothopanus nambi of African Origin.Chemistry & biodiversity · 2026Article
- Article
- New sordarialean lineageIMA fungus · 2026Article
- Biodiversity-Driven Natural Products and Bioactive Metabolites.Plants (Basel, Switzerland) · 2025Review
- Cordypyridones E-J: Antibiofilm 2-Pyridone Alkaloids from the Nematode Antagonistic FungusJournal of natural products · 2025Article
- The Khamkhains, Neurotrophic Drimane-Type Sesquiterpenoids Derived from a Polyporaceous Basidiomycete Originating from Thailand.Journal of natural products · 2025Article
- Integrated multi-omics reveals flavonoid-dominated defense strategies in Coptis chinensis under Fusarium root rot infection.BMC plant biology · 2025Article
- Detection ofAnnals of Saudi medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural product discovery from fungi for drug development and description of novel chemistry has been a tremendous success. This success is expected to accelerate even further, owing to the advent of sophisticated technical advances of technical advances that recently led to the discovery of an unparalleled biodiversity in the fungal kingdom. This review aims to give an overview on i) important secondary metabolite-derived drugs or drug leads, ii) discuss the analytical and strategic framework of how natural product discovery and drug lead identification transformed from earlier days to the present, iii) how knowledge of fungal biology and biodiversity facilitates the discovery of new compounds, and iv) point out endeavors in understanding fungal secondary metabolite chemistry in order to systematically explore fungal genomes by utilizing synthetic biology. An outlook is given, underlining the necessity for a collaborative and cooperative scenario to harness the full potential of the fungal secondary metabolome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.